Oncology

Replacing carmustine with cisplatin in BEAM ((carmustine, etoposide, cytarabine, and melphalan) conditioning could be more cost-effective for patients.

Acalabrutinib plus venetoclax, with or without obinutuzumab, demonstrated significant improvements in progression-free survival.

A report from SkyQuest Technology highlights the growth in the oncology and insulin spaces, indicating they will contribute to the most growth.

The drug also receives orphan drug designation for the treatment of pancreatic neuroendocrine tumors and a Prescription Drug User Fee Act target action date of April 3, 2025.

The findings highlight the potential for developing more efficacious combination treatments for patients with glioblastoma.

The trial is evaluating the success of BNT111 and cemiplimab in treating unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment.

In the first half of 2024, the FDA approved 23 novel drugs for conditions including alopecia areata, Alzheimer disease, small cell lung cancer, bladder cancer, and more.

Investigators determine the efficacy and safety of the combination in a 2-phase trial.

Afamitresgene autoleucel (afami-cel) is a novel cell therapy for the treatment of patients with synovial sarcoma.

Afami-cel was approved in conjunction with MAGE-A4 IHC 1F9 pharmDx, a diagnostic tool that can identify patients eligible to receive the treatment for synovial sarcoma.

The diagnostic tool can aid the identification of patients with synovial sarcoma who may be eligible for treatment with newly approved afamitresgene autoleucel.

The RUBY trial will continue and analyze the overall population survival after treatment with the drug combination.

The findings provide guidance for clinicians and patients when navigating therapeutic options to establish treatment plans.

Pharmacists' roles in community-based cancer centers are expanding, with a more significant role in managing complex treatment regimens, ensuring comprehensive patient care, navigating drug shortages, and collaborating with multidisciplinary teams to enhance patient outcomes and streamline health care operations.

The drug previously received breakthrough therapy designation for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia that is in chronic phase.

The decision is based on positive results from the PERSEUS trial.

The designation is based off positive results from the RAMP 205 trial presented at the ASCO Annual Meeting.

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.

Advancements in treatment include immune checkpoint inhibitors and BRAF/MEK inhibitors, though resistance remains a challenge, with lifileucel recently approved for previously treated metastatic cases.

The similarities were shown for both the US formulation and the EU formulation.

The blood test offers patients advanced screening methods capable of detecting colorectal cancer in its earlier stages.

Increased levels of absolute lymphocyte count are associated with improved response to BCMA-targeted CAR T-cell therapy.

The new approach could optimize precision medicine and lead to better outcomes across a variety of disease states.

AIC100 could meet an unmet medical need to effectively treat individuals with anaplastic thyroid cancer — the most aggressive form of the disease.

β2-microglobulin may be an effective indicator of coagulation dysfunction in patients with newly diagnosed multiple myeloma (NDMM).

Proper timing and vaccine selection are crucial for optimal immune responses.

Educators should prioritize integrating social determinants of health (SDOH) for the next generation of pharmacists.

There were positive efficacy and safety results for tivozanib monotherapy consistent with previous analyses.

In a study of Swedish patients with mantle cell lymphoma, the participants faced a heightened risk of infection after their diagnosis and associated treatment for the disease.

Both economic factors and supply chain fragility play a role.